The board of directors of Akeso, Inc. announced that the National Medical Products Administration (NDA) of China has accepted the New Drug Application (NDA) for the Company's independently-developed ebdarokimab injection (research and development code: AK101), a wholly human IgG1 monoclonal antibody targeting IL-12/IL-23 for the treatment of moderate to severe plaque psoriasis. Ebdarokimab is the sixth in-house developed innovative drug which has received NDA approval or submitted NDA application. A total of 5 clinical studies of ebdarokimab in patients with plaque psoriasis were conducted, of which 2 were pivotal Phase III clinical studies to evaluate the key efficacy data of ebdarokim AB for 16 weeks and long-term 52 weeks in patients with moderate-to-severe plaque psoriasis.

Ebarokimab can improve the quality of life of patients while improving skin condition. The number of patients with psoriasis in China has exceeded 6 million, and the prevalence increases continuously. Psoriasis is a chronic and disabling disease which negatively impacts on patients' quality of life, which results in an overall heavy burden of disease for patients.

In 2022, the market size of psoriasis treatment medications in China was approximately USD 1.1 billion, and is expected to reach USD9.5 billion in 2030. As the first domestic new IL-12/IL- 23 monoclonal antibody with outstanding efficacy and safety, ebdarokimab, is expected to provide more efficient, safe, convenient and economical treatment for patients in China.